结直肠癌（CRC）是全球主要的恶性疾病之一，具有高转移率和恶劣预后。治疗选项包括手术，通常在晚期CRC之后跟随化疗。经过治疗后，癌细胞可能会对5-氟尿嘧啶（5-FU）、奥沙利铂、顺铂和伊立替康等经典细胞毒素药物产生耐药性，导致化疗失败。因此，对于保护健康的再敏化机制，包括辅助使用天然植物化合物，有很高的需求。印度姜黄植物中提取的两种多酚类姜黄成分——卡莱宾A和姜黄素，展示了多功能的抗炎和抗癌能力，其中包括对抗CRC的能力。在深入了解它们的表观遗传学调节全面促进健康的作用后，本文将多靶向姜黄衍生的化合物的功能性抗CRC机制与单靶向经典化疗药物进行比较。此外，通过聚焦卡莱宾A和姜黄素对5-FU、奥沙利铂、顺铂和伊立替康进行化敏化或重新敏化CRC细胞的能力，阐明了对化疗药物耐受性的逆转。两种多酚类物质通过调节炎症、增殖、细胞周期、癌症干细胞和凋亡信号传导，增强CRC细胞对标准细胞毒素药物的接受性，将它们从耐药转化为非耐药性CRC细胞。因此，可将卡莱宾A和姜黄素作为预临床和临床试验的一部分进行测试，以评估其在治疗晚期转移性CRC患者的辅助化疗中克服癌症化疗耐药性的能力。本文还解释了将姜黄成分姜黄素或卡莱宾A作为化疗的附加治疗用于晚期转移性CRC患者的未来展望。版权所有©2023 Elsevier Inc.

Colorectal cancer (CRC) is one of the leading malignant diseases worldwide with a high rate of metastasis and poor prognosis. Treatment options include surgery, which is usually followed by chemotherapy in advanced CRC. With treatment, cancer cells could become resistant to classical cytostatic drugs such as 5-fluorouracil (5-FU), oxaliplatin, cisplatin, and irinotecan, resulting in chemotherapeutic failure. For this reason, there is a high demand for health-preserving re-sensitization mechanisms including the complementary use of natural plant compounds. Calebin A and curcumin, two polyphenolic turmeric ingredients derived from the Asian Curcuma longa plant, demonstrate versatile anti-inflammatory and cancer-reducing abilities, including CRC-combating capacity. After an insight into their epigenetics-modifying holistic health-promoting effects, this review compares functional anti-CRC mechanisms of multi-targeting turmeric-derived compounds with mono-target classical chemotherapeutic agents. Furthermore, the reversal of resistance to chemotherapeutic drugs was presented by focusing on calebin A's and curcumin's capabilities to chemosensitize or re-sensitize CRC cells to 5-FU, oxaliplatin, cisplatin, and irinotecan. Both polyphenols enhance the receptiveness of CRC cells to standard cytostatic drugs converting them from chemoresistant into non-chemoresistant CRC cells by modulating inflammation, proliferation, cell cycle, cancer stem cells, and apoptotic signaling. Therefore, calebin A and curcumin can be tested for their ability to overcome cancer chemoresistance in preclinical and clinical trials. The future perspective of involving turmeric-ingredients curcumin or calebin A as an additive treatment to chemotherapy for patients with advanced metastasized CRC is explained.Copyright © 2023. Published by Elsevier Inc.